In our study, we found that those lower than 30 years old had higher rates of HER2 expression; lower ER- and PR-positive individuals; higher stage and grade; higher rates of BCS, SLNB, and radiotherapy; lower rates of hormone therapy; and higher lymphovascular invasion compared to 30–60-year-old and > 60-year-old BC patients. Here, ERBB2 is linked to breast cancer.